Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 10/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181116 | 0.90 | LRRK2 (0.50) | MRGPRX4LRRK2AKR1C3LMNAHPGD | |
| SCHEMBL1154081 | 0.89 | AKR1C3 (0.52) | NR4A2MRGPRX4AKR1C3DNMT3APTGER1 | |
| SCHEMBL10305303 | 0.87 | AKR1C3 (0.52) | MRGPRX4AKR1C3LMNADNMT3APTGER1 | |
| SCHEMBL1154137 | 0.87 | AKR1C3 (0.59) | MRGPRX4AKR1C3DNMT3APTGER1 | |
| SCHEMBL1153994 | 0.86 | AKR1C3 (0.51) | MRGPRX4AKR1C3DNMT3APTGER1 | |
| SCHEMBL1154192 | 0.86 | DNMT3A (0.53) | MRGPRX4AKR1C3DNMT3APTGER1 | |
| SCHEMBL1154383 | 0.85 | DNMT3A (0.56) | MRGPRX4AKR1C3DNMT3APTGER1 | |
| SCHEMBL1153664 | 0.85 | PTGER4 (0.59) | MRGPRX4LRRK2AKR1C3LMNADNMT3A | |
| SCHEMBL1153860 | 0.84 | MRGPRX4 (0.50) | MRGPRX4AKR1C3DNMT3APTGER1 | |
| SCHEMBL1154704 | 0.84 | AKR1C3 (0.50) | MRGPRX4AKR1C3LMNADNMT3APTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | claimed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | claimed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | claimed |
| EP-2215065-A1 | CCR10 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | claimed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2215065-A1 | CCR10 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039851-A1 | CCR10 ANTAGONISTS | CCR10, CCR1, CCR4 | NR4A2 924/4885MRGPRX4 64/4885LRRK2 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.